Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PrEP-PP: PrEP in Pregnant and Breastfeeding Women
NCT03826199Phase 4Completed
- Sponsor
- University of California, Los Angeles
- Start
- Aug 2019
- Primary completion
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of emtricitabine + tenofovir disoproxil in human immunodeficiency virus infection (HIV), sponsored by University of California, Los Angeles. Primary endpoints: PrEP Retention at 18 months and PrEP Adherence at 3 months. Started Aug 2019; status: completed.
02
Drugs
emtricitabine + tenofovir disoproxil
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT03826199.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03826199.